Pretreatment in 47 MPN-blast phase cases and frequency of 17p and 7q deletions
| Pretreatment | ||||
| Hydroxyurea | − | + | − | + |
| Alkylating agents | − | − | + | + |
| SNP-array alteration (17p vs 7q) | ||||
| No del(17)(p), no del(7(q) | 17 | 16 | 0 | 1 |
| del(7)(q) | 2 | 2 | 2 | 2 |
| del(17)(p) | 0 | 4* | 0 | 1* |
| del(17)(p) and del(7)(q) | 0 | 0 | 0 | 0 |
| Pretreatment | ||||
| Hydroxyurea | − | + | − | + |
| Alkylating agents | − | − | + | + |
| SNP-array alteration (17p vs 7q) | ||||
| No del(17)(p), no del(7(q) | 17 | 16 | 0 | 1 |
| del(7)(q) | 2 | 2 | 2 | 2 |
| del(17)(p) | 0 | 4* | 0 | 1* |
| del(17)(p) and del(7)(q) | 0 | 0 | 0 | 0 |
Numbers of blast-phase patients are presented.
MPN indicates myeloproliferative neoplasm; and SNP, single nucleotide polymorphism.
A total of 5 cases with del(17)(p) pretreated with hydroxyurea (P = .035).